Proceedings and Data From The Schizophrenia Summit:
A Critical Appraisal to Improve the Management of Schizophrenia

CME Background Information

[PDF]

ARTICLES

4 Scope and Panel

[PDF]

5 Introduction

[PDF]

6 Statement 1: Identification of the Earliest Prodromal Phase of Schizophrenia Is Feasible

[PDF]

10 Statement 2: Schizophrenia Is a Neurodegenerative Disease Resulting in Brain Changes That Parallel Symptom Progression and Functional Decline

[PDF]

13 Statement 3: Cognitive Impairment, Especially Executive Dysfunction and Memory Loss, Is a Key Diagnostic Component of Schizophrenia

[PDF]

16 Statement 4: Genetic Factors Are the Best Established Etiologic Determinants of Schizophrenia

[PDF]

20 Statement 5: Neuroimaging Is a Tool for Elucidating Biological and Genetic Mechanisms of Illness and Treatment Response

[PDF]

24 Statement 6: Atypical Antipsychotic Drugs Are Neuroprotective in Patients Diagnosed With Schizophrenia

[PDF]

27 Statement 7: Treatment in the Prodromal Phase of Schizophrenia Improves Patient Outcomes

[PDF]

31 Statement 8: Patients With Treatment-Resistant Schizophrenia Require Combination Antipsychotic Treatment

[PDF]

34 Statement 9: Improvement in Cognitive Function Is an Essential Treatment Target in Patients With Schizophrenia

[PDF]

37 Statement 10: Managing Substance Abuse Is a Key Target of Treatment

[PDF]

40 Summary

[PDF]

41 References

[PDF]

46 Financial Disclosure and Acknowledgment

[PDF]

CME Section

47 Posttest and Evaluation

[PDF]